Perspective Therapeutics, Inc.
CATX NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.21
KIRA · Stoqly’s AI analyst, in plain words
- Perspective Therapeutics, Inc. had $0.9M of revenue in fiscal 2025, down 39.2% on the year before. Over five years, revenue changed −38.5% a year on average.
- Its operating margin was −12,846.6%, down 6,595.8 pts: of every 100 in sales, about −12,847 is left after running the business.
- Perspective Therapeutics, Inc. lost $103M in fiscal 2025.
- Free cash flow was −$95.2M in fiscal 2025, −10,773.0% of revenue.
- Perspective Therapeutics, Inc. has $143M more cash than debt.
Market cap
$146M
P/E
—
Revenue
$0.9M
Net income
−$103M
Free cash flow
−$95.2M
Operating margin
−12,846.6%
Perspective Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−39.2%
No. Sales fell 39.2% last year.
Does it make a profit?
−11,665.3%
No. It lost money last year.
Does profit turn into cash?
−10,773.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Perspective Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- Perspective Therapeutics, Inc.
- CIK
- 0000728387
Perspective Therapeutics, Inc. · CATX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY20 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $10.1M | $10.8M | $1.4M | $1.5M | $0.9M |
| Revenue growth | 3.9% | — | −86.7% | 1.4% | −39.2% |
| Gross margin | 50.9% | 0.0% | 100.0% | — | — |
| Operating margin | −34.3% | −59.5% | −2,855.0% | −6,250.8% | −12,846.6% |
| Net income | −$3.4M | −$7.3M | −$46.5M | −$79.3M | −$103M |
| Net margin | −33.7% | −67.4% | −3,243.2% | −5,452.5% | −11,665.3% |
| Diluted EPS | −$0.03 | — | −$1.74 | −$1.23 | −$1.40 |
| Cash | |||||
| Cash from operations | −$2.8M | −$7.7M | −$36.9M | −$18.3M | −$82.5M |
| Capital expenditure | $0.4M | $0.3M | $1.1M | $54.4M | $12.7M |
| Free cash flow | −$3.2M | −$8.0M | −$38.0M | −$72.7M | −$95.2M |
| FCF margin | −32.0% | −73.9% | −2,648.9% | −5,000.6% | −10,773.0% |
| Share count change | 53.6% | — | — | 140.7% | 14.6% |
| Debt and strength | |||||
| Cash and short-term investments | $63.8M | $43.8M | $9.2M | $227M | $145M |
| Debt incl. finance leases | — | — | $1.7M | $1.7M | $1.6M |
| Shareholders' equity | $67.4M | $54.6M | $75.2M | $291M | $207M |
| Current ratio | 37.4x | 17.1x | 1.1x | 12.7x | 5.2x |
| Interest coverage | — | — | −487.4x | — | — |
| Returns and quality | |||||
| Return on capital | — | — | −47.8% | −109.7% | −140.4% |
| Return on equity | −9.3% | −13.3% | −71.6% | −43.3% | −41.4% |
| Return on tangible equity | −5.0% | −13.3% | −91.6% | −27.3% | −49.9% |
| Piotroski F-score | 3 | — | 2 | 4 | 1 |
| Altman Z'' | 25.1 | 15.6 | −4.3 | 6.1 | −0.4 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$1.3M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Perspective Therapeutics, Inc. · CATX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.21 a share, the company is worth $146M.
Source: SEC EDGAR XBRL filings (CIK 0000728387). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.